Lang G E
Augenklinik, Universitätsklinikum Ulm.
Klin Monbl Augenheilkd. 2011 Sep;228(9):793-800. doi: 10.1055/s-0031-1281712. Epub 2011 Sep 12.
The therapeutic options for retinal vascular diseases have changed due to new study results and the approval of dexamethasone (Ozurdex®) and ranibizumab (Lucentis®) by the EU commission for visual loss caused by macular oedema in retinal vein occlusion. In addition to laser treatment, we have now two approved drugs for the treatment of macular oedema. Therefore it is important to make decisions about the best treatment in retinal vein occlusion. This necessitates knowledge of the posology of the drug and assessment of the advantages and risks of the different treatment modalities. Therefore it is important to know the efficacy and safety data of the different therapies. The approval of dexamethasone and ranibicumab for the treatment of macular oedema in branch and central retinal vein occlusions improves the chances for the outcome, especially concerning visual acuity. The new results from the dexamethasone and ranibizumab studies in matters of efficacy and safety and treatment recommendations are described.
由于新的研究结果以及地塞米松（Ozurdex®）和雷珠单抗（Lucentis®）被欧盟委员会批准用于治疗视网膜静脉阻塞引起的黄斑水肿导致的视力丧失，视网膜血管疾病的治疗选择发生了变化。除了激光治疗外，我们现在有两种获批用于治疗黄斑水肿的药物。因此，对于视网膜静脉阻塞的最佳治疗做出决策很重要。这需要了解药物的剂量学，并评估不同治疗方式的优缺点。因此，了解不同疗法的疗效和安全性数据很重要。地塞米松和雷珠单抗获批用于治疗分支和中央视网膜静脉阻塞的黄斑水肿，改善了治疗结果的可能性，尤其是在视力方面。本文描述了地塞米松和雷珠单抗研究在疗效、安全性和治疗建议方面的新结果。
